Kornimate/medical-research-clean huggingface dataset:
the prehospital administration of normobaric oxygen in suspected stroke

Conditions: Acute Stroke; Ischemic Stroke, Acute

Summary: the primary purpose of this study is to explore the feasibility and safety of normobaric oxygen therapy (nbo) under pre-hospital condition in patients with suspected stroke.

despite the application of thrombolytic drugs and endovascular treatment, there is still a gap between the successful recanalization and ideal clinical outcomes for stroke patients. neuroprotective treatment is considered as a promising adjuvant to ameliorate this situation. previous researches demonstrated the neuroprotective effects of normobaric hyperoxia (nbo) in animal models from multiple perspectives. moreover, nbo is distinctive for its ubiquity, conveniency, high compatibility, and wide adaptability, making it superior to other neuroprotective interventions in a pre-hospital setting. therefore, the investigators conducted this pilot study to further explore the feasibility and safety of nbo under a pre-hospital condition in patients with suspected stroke.

Eligibility criteria:
inclusion criteria: 1. age 18 years or more. 2. suspected stroke screened by the "gaze- face arm speech time" scale (g-fast score ≥ 1). 3. within 24 hours of symptom onset 4. spo2 \> 94%. exclusion criteria: 1. coma: glasgow coma score (gcs) \< 8. 2. hypoglycemia: blood glucose \< 2.8mmol /l. 3. known history of seizure. 4. recent stroke or brain trauma within past 30 days. 5. previous modified rankin scale (mrs) ≥2. 6. rapid improvement of neurological dysfunction (deficit present less than 15 min). 7. unstable vital signs. 8. known respiratory distress, respiratory dysfunction, or any contraindications to high-flow oxygen inhalation therapy. 9. patient unable to cooperate with the trial procedure. 10. any condition which might increase the risk to the patient in the judgment of the investigator. 11. patient or available legally authorized representative unable to provide written or witnessed oral consent.

Keywords: acute stroke normobaric oxygen stroke neuroprotection
is there a difference in oocyte quality? a comparison of two aspiration needle gauges

Conditions: Infertility

Summary: the aim of this study is to determine whether different needle gauges influences the quality of the aspirated oocytes during in-vivo fertilization (ivf).


Eligibility criteria:
inclusion criteria: * fertility treatment * antral follicle count exclusion criteria: * women who refuse to participate
oxymatrine plus lamivudine combination therapy versus lamivudine monotherapy for chronic hepatitis b infected subjects

Conditions: Chronic Hepatitis B

Summary: the purpose of this study is to evaluate the efficacy of oxymatrine plus lamivudine combination therapy and whether it could lower the incidence of lamivudine long-term resistance compared to lamivudine monotherapy.

group a (lamivudine monotherapy): lamivudine (manufacturer: glaxosmithkline) 100mg po, qd. group b (oxymatrine + lamivudine combination therapy): lamivudine (manufacturer: glaxosmithkline) 100mg po, qd; oxymatrine capsules (chia tai tianqing pharmaceutical group co., ltd) 200 mg, po, tid. total subjects: 200, 100 patients randomized in each group.

Eligibility criteria:
inclusion criteria: 1. 18 to 60 years old. 2. subjects diagnosed as chronic hepatitis b according to 2000 xi'an conference guidelines: management of chronic hepatitis b. alanine transaminase \>80 iu/l, total bilirubin\ 1×10\^5copies/ml; haven't been treated with antiviral therapy within 6 months before screening. 3. able to give written informed consent and to comply with the study protocol. 4. women of childbearing potential (wocbp) must be using an adequate method of contraception to avoid pregnancy throughout the study. exclusion criteria: 1. evidence of hepatocellular carcinoma 2. clinical symptoms of decompensated liver disease at screening, including but not limited to: serum bilirubin≥1.5 x upper limit of normal, prothrombin time of greater than 2 seconds prolonged, a serum albumin\< 32g/l, or a history of ascites, variceal bleeding, or hepatic encephalopathy; 3. alanine transaminase\>10 x upper limit of normal at screening or history of transient hepatic decompensation caused by acute exacerbation; 4. hemoglobin\< 10g/dl, neutrophil count\<1.5 × 10\^9/l, platelet count\< 80 × 10\^9/l; 5. evidence of active liver disease from other causes, including co-infection with hepatitis a virus, co-infection with hepatitis e virus, co-infection with hepatitis c virus, co-infection with hepatitis d virus, co-infection with hiv, autoimmune hepatitis (antinuclear antibody titer\> 1:100); 6. use of immunosuppressors, immunomodulators (including interferon or thymosin) within 6 months before enrollment.

Keywords: oxymatrine capsules, lamivudine, chronic hepatitis b
the effectiveness of acupressure on reducing pain and improving gastrointestinal function after laparoscopic surgery

Conditions: Postoperative Pain

Summary: the purpose of the study is to explore the effect if acupressure reducing pain after laparoscopic surgery. the study is designed as an experimental research with repeat measurement design. the patients who are eligible for laparoscopic for general surgery and colorectal surgery in a medical center in the central part of taiwan. the intervention of the research starts from the first date of postoperative day and the patient has the postoperative pain. the participant will be randomized into experimental group and control group. these two groups will be given true acupressure and sham acupressure twice daily. the participant will be observation the postoperative pain and postoperative recovery.

laparoscopic is increasing in this decade. the surgical trauma caused postoperative pain which cannot be avoid. it is the significant challenge and the thorny issue of the healthcare providers, also, be discussed for many decades. several clinical researches have been verified acupuncture and related method have been as adjuvant efficacy treatment for decreasing postoperative pain. acupressure is the method of the thumb put acupoint, and therapeutic effectiveness is similar to acupuncture. acupressure is allowed to a nurse work independently due to noninvasive treatment. however, the less of the clinical studies explore the efficacy of acupressure reducing the postoperative pain after laparoscopic. the result of the research will provide the efficacy of reducing postoperative laparoscopic pain and wish to improve the quality of care.

Eligibility criteria:
inclusion criteria: * laparoscopic surgery on the organ of liver, gastric, small intestine, colon under general anaethesia * the american society of anesthesiologists (asa) :i - iii * above 20 years old * the state of consciousness is alert * chinese or taiwanese speaker exclusion criteria: * surgical procedure: resection, low anterior resection, roux-en-y gastric bypass and whipple procedure (pancreaticoduodenectomy) * postoperative length of hospital stay less than 3 days * patient have pregnant, maternity, breastfeeding, chronic pain history, coagulation disorder or skin injury on the acupoints. * drug abuse, alcoholism * patient-controlled analgesia

Keywords: laparoscopic surgery post-operative pain acupressure analgesia
a study of tpx-0131, a novel oral alk tyrosine kinase inhibitor, in patients with alk+ advanced or metastatic nsclc

Conditions: Non Small Cell Lung Cancer; Non-Small Cell Lung Cancer; NSCLC; Advanced Solid Tumor; Metastatic Solid Tumor; ALK Gene Mutation

Summary: a phase 1, first-in-human, open-label study to evaluate the safety, tolerability, pk, and efficacy of the novel alk inhibitor tpx-0131 in pretreated subjects with alk+ advanced or metastatic non-small cell lung cancer (nsclc).

phase 1 dose escalation: to evaluate the overall safety profile, efficacy of tpx-0131 in pretreated subjects with alk+ advanced or metastatic nsclc.

Eligibility criteria:
inclusion criteria: * age ≥ 18 (or as required by local regulation). * histological or cytological confirmation of advanced/metastatic alk+ nsclc. * pretreated with up to three prior lines of an alk tki treatment, including at least one prior line of a second or third-generation alk tki (alectinib, brigatinib, ensartinib, or lorlatinib) in phase 1. * ecog performance status ≤ 1. * existence of measurable or evaluable disease (according to response evaluation criteria in solid tumors \[recist v1.1\] criteria). * subjects with asymptomatic cns metastases and/or asymptomatic leptomeningeal carcinomatosis are eligible. * adequate organ function. exclusion criteria: * major surgery within four weeks of the start of tpx-0131 treatment. * clinically significant cardiovascular disease * any of the following cardiac criteria: * mean resting corrected qt interval (qtc) \> 470 msec obtained from three ecgs and any factors that increase the risk of qtc prolongation or arrhythmic events * any clinically important abnormalities in rhythm, conduction, or morphology of resting ecg * known clinically significant active infections not controlled with systemic treatment (bacterial, fungal, viral including hiv positivity). * gastrointestinal disease or other malabsorption syndromes that would impact drug absorption. * subjects being treated with or anticipating the need for treatment with strong cyp3a4 inhibitors or inducers. * subjects with current or anticipated need for drugs that are sensitive cyp2c9 substrates with narrow therapeutic indices.

Keywords: non small cell lung cancer non-small cell lung cancer nsclc advanced non-small cell lung cancer advanced/metastatic disease lung cancer metastatic solid tumor advanced solid tumor alk gene fusion alk inhibitor tpx-0131 alk tki alk tyrosine kinase inhibitor
study of abt-199 (gdc-0199) in combination with azacitidine or decitabine (chemo combo) in subjects with acute myelogenous leukemia (aml)

Conditions: Acute Myelogenous Leukemia; Myelogenous Leukemia; Treatment Naive AML

Summary: this is a phase 1b, open-label, non-randomized, multicenter study to evaluate the safety and pharmacokinetics of orally administered venetoclax (abt-199) combined with decitabine or azacitidine and the preliminary efficacy of these combinations. in addition, there is a drug-drug interaction (ddi) sub-study only at a single site, to assess the pharmacokinetics and safety of venetoclax (abt-199) in combination with posaconazole.


Eligibility criteria:
inclusion criteria: * subjects must have confirmation of acute myeloid leukemia (aml) by who criteria and be ineligible for treatment with a standard cytarabine and anthracycline induction regimen due to co-morbidity or other factors. * subject must have received no prior treatment for aml with the exception of hydroxyurea * subjects must have eastern cooperative oncology group (ecog) performance status of 0 to 2 for subjects greater than or equal to 75 years of age, or 0 to 3 for subjects greater than or equal to 60 to 74 years of age * subject must have adequate kidney and liver function as described in the protocol exclusion criteria: * subject has received treatment with the following hypomethylating agent and/or chemo therapeutic agent for for an antecedent hematologic disorder (ahd) (subjects may have been treated with other agents for ahd i.e., myelodysplastic syndrome \[mds\]) * subject has history of myeloproliferative neoplasm (mpn). * subject has favorable risk cytogenetics as categorized by the national comprehensive cancer network guidelines version 2, 2014 for aml. * subject has t(8;21), inv(16), t(16;16) or t(15;17) karyotype abnormalities. * subject has acute promyelocytic leukemia. * subject has known active central nervous system involvement with aml. * subject has received a strong and/or moderate cyp3a inducer within 7 days prior to the initiation of study treatment. * subject has a history of other malignancies prior to study entry, with the exception of: * adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of breast; * basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin; * previous malignancy confined and surgically resected (or treated with other modalities) with curative intent. * subject has a white blood cell count \> 25 × 10\^9/l. note: hydroxyurea is permitted to meet this criterion.

Keywords: acute myelogenous leukemia aml myelogenous leukemia abt-199 gdc-0199 treatment naive aml untreated aml venetoclax venclexta
glucose metabolism and quality of life in healthy women

Conditions: Healthy

Summary: polycystic ovary syndrome (pcos) is a common endocrine disorder in premenopausal women. women with pcos often have problems with fertility, unwanted hair growth, and irregular menstrual cycle. pcos is associated with obesity, changes in glucose metabolism and low quality of life. in the present study, hormonal profile, glucose metabolism, adrenal functon, androgen levels, cortisol metabolism, anflammatory response, ovarian morphology, body composition, pfysical activity and quality of life is studied in 40 healthy women. the results will be compared with results from studies on women with pcos in order to investigate any differences in these parametres.


Eligibility criteria:
inclusion criteria: * healthy * no medications * regular menstrual cycle * no hair growth problems * bmi 18-35 kg/m2 exclusion criteria: * medication * diabetes mellitus * signs of pcos * bmi \ 35

Keywords: healthy women quality of life glucose metabolism adrenal reactivity physical activity body composition
an observational registry assessing the impact of pylarify® (piflufolastat f18) pet in patients with prostate cancer

Conditions: Prostate Cancer

Summary: the goal of this observational research is to assess the real-world clinical utility of pylarify pet through evaluation of long-term outcomes for prostate cancer patients who are eligible for a psma/pet scan. participants will be enrolled at their physician's office at the time of referral for pylarify pet and will be followed for up to 5 years. data concerning their prostate cancer diagnostics and treatment will be collected at 6-month intervals.


Eligibility criteria:
inclusion criteria: patients must meet all the following inclusion criteria: 1. biological male at birth ≥ 21 years of age 2. histopathological confirmed prostate adenocarcinoma 3. patients meeting the enrollment criteria for either cohort 1 or cohort 2: 1. cohort 1: patients who are newly diagnosed with prostate cancer (and have suspected metastases per the physician's discretion per standard of care assessment) and have not yet initiated any prostate cancer treatment and are referred to undergo pylarify pet for identification of suspected metastases. or 2. cohort 2: patients who have previously received treatment for prostate cancer and are referred to undergo pylarify pet or have received pylarify pet for suspected recurrence of prostate cancer (based on an elevated psa) within 60 days of consent to enroll in the registry 4. life expectancy ≥ 6 months as determined by the investigator 5. able and willing to provide informed consent and comply with the protocol requirements. exclusion criteria: patients meeting any of the following exclusion criteria are not eligible for enrollment in this study: 1. patients who are referred for psma pet and undergo a psma pet with a radioactive agent other than pylarify 2. patients who have histological evidence of neuroendocrine prostate cancer (nepc) (small cell/ductal variant) 3. patients with any medical condition or other circumstances that, in the opinion of the investigator, compromise the safety of compliance of the patient to produce reliable data or completing the study.
effect of massage therapy on fatigue and sleep quality in patients with heart failure in intensive care unit

Conditions: Massage; Heart Failure

Summary: the purpose of this study was to explore the effect of massage therapy on fatigue and sleep quality in patients with heart failure in the intensive care unit. the study design was a randomized control trial and repeated measurements. a convenience sampling was used to recruit heart failure patients with new york heart association (nyha) ii-iii from the intensive care unit of a regional teaching center. in addition to routine turning, patients in the experimental group received daily back massage intervention for 10 minute, once a day; the control group maintained usual care. the data collection included three time points: baseline, 4th and 7th day after the intervention. research tools include basic personal data, piper fatigue scale and pittsburgh sleep quality scale.

the purpose of this study was to explore the effect of massage therapy on fatigue and sleep quality in patients with heart failure in the intensive care unit. the study design was a randomized control trial and repeated measurements. a convenience sampling was used to recruit heart failure patients with new york heart association (nyha) ii-iii from the intensive care unit of a regional teaching center. in addition to routine turning, patients in the experimental group received daily back massage intervention for 10 minute, once a day; the control group maintained usual care. the data collection included three time points: baseline, 4th and 7th day after the intervention. research tools include basic personal data, piper fatigue scale and pittsburgh sleep quality scale. data will be analyzed by descriptive statistics, chi-square test, pearson product correlation, one-way anova, independent sample t test, repeated measure anova, and generalized estimating equation (gee)。

Eligibility criteria:
inclusion criteria: * patients with heart failure diagnosed by a physician and grade ii to iii according to nyha classification, and those who can perform massage therapy after the physician's evaluation * over 20 years old * a person who has a clear consciousness and can communicate * those who are willing to accept the implementation of this research plan exclusion criteria: * people with sleep disorders * people with mental or cognitive impairment * patients who use sedatives or neuroleptics * patients with unstable angina, myocardial infarction, and unstable vital signs * those who are unconscious and unable to communicate.

Keywords: heart failure massage fatigue sleep quality
modulation of free fatty acids in heart failure patients with diabetes: "effect on left ventricular function"

Conditions: Heart Failure; Diabetes

Summary: the investigators wish to investigate the the short term effect of low circulating free fatty acids in congestive heart failure patients with type 2 diabetes. hypothesis: low levels of circulating free fatty acids decrease myocardial and peripheral muscle lipid content, improves cardiac performance and exercise capacity.


Eligibility criteria:
inclusion criteria: * ejection fraction at or lower than 45% * type 2 diabetes exclusion criteria: * known s-creatinine \>220mm * known s-alanine aminotransferase \>3 times normal upper limit * other disabilitating conditions * pregnancy * insulin treatment
study of everolimus in de novo renal transplant recipients

Conditions: End Stage Renal Failure With Renal Transplant

Summary: in the present study, the investigators propose a conversion scheme with 50% reduction in cni dosage until adjustment of everolimus dosage, in order to reach a trough blood level of 6-10 ng/ml, thus avoiding overimmunosuppression or alternatively breakthrough rejection episodes. the hypothesis of this study is to demonstrate that the therapeutic regimen with myfortic® and certican® significantly improves renal function compared with the standard regimen of cni.


Eligibility criteria:
inclusion criteria: * renal transplant patients * age between 18 and 85 years * recipients of living or deceased donors * donor under the age of 85 years * panel reactivity antibodies (pra) over or equal to 30% * 4-5 months post-transplant * cni-based immunosuppressive regimen * stable graft function (creatinine lower than 2.0 mg/dl) * no currently acute rejection * proteinuria lower than 800mg/d * no laboratory or physical clinically significant signs presented for the last 2 months before screening. exclusion criteria: * recipient of multiple organs * recipient with a history of focal segmental glomerulosclerosis or membranous glomerulonephritis * presence of uncontrolled hypercholesterolemia (≥350 mg/dl)hypertriglyceridemia (over or equal to 500 mg/dl) * patients with egfr lower than 40 ml/min/1.73m2 * evidence of acute rejection within 2 months before screening * thrombocytopenia (lower than 75,000/mm3) * neutropenia (lower than 1,500/mm3) * leukocytopenia (lower than 2500/mm3) * anemia (hemoglobin lower than 6.0g/dl) * severe liver disease (including transaminases or bilirubin equal or over 3 times normal) * proteinuria over 800mg/dl * systemic infection or pneumonia (active infection) * positive for hepatitis b, hepatitis c or hiv.

Keywords: immunosuppression chronic kidney disease renal transplant
observational study to evaluate, under real-world practice conditions, the safety and effectiveness of regorafenib in patients diagnosed with unresectable hepatocellular carcinoma (uhcc)

Conditions: Liver Neoplasms

Summary: observational study to evaluate, under real-world practice conditions, the safety and effectiveness of regorafenib in patients diagnosed with unresectable hepatocellular carcinoma (uhcc)


Eligibility criteria:
inclusion criteria: * patients with confirmed diagnosis of unresectable hcc * physician-initiated decision to treat with regorafenib (prior to study enrollment) exclusion criteria: * participation in an investigational program with interventions outside of routine clinical practice * past treatment with regorafenib

Keywords: liver cancer unresectable hepatocellular carcinoma real-world practice conditions safety and effectiveness management and treatment of liver cancer
predictability of distalization and derotation of the carriere motion appliance.

Conditions: Dental Malocclusion

Summary: to analyze the distalization or distal tooth displacement and derotation angle produced by carriere motion appliance® (cma) by using a repeatable and reproducible measurement digital technique.

15 patients with class ii molar and canine relationship were submitted to orthodontic treatment with cma. all patients were exposed preoperatively (stl1) and postoperatively (stl2) to a digital impression and afterwards were uploaded into a specific cephalometric software to allow the automatic mesh networks alignment of the stl digital files. subsequently, the distal tooth displacement of upper canines and first upper molars and also the derotation angle of first upper molars were measured. the repeatability and reproducibility were analyzed by gage r\&r statistical analysis.

Eligibility criteria:
inclusion criteria: * growing patients * late mixed dentition or permanent dentition * fully erupted definitive molars * no history of previous orthodontic treatment * complete pre- and post-treatment records (digital study models) * dental class ii relationship. exclusion criteria: * permanent dentition * adults * dental class i, iii

Keywords: class ii malocclusion carriere motion appliance distalization derotation